Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Tar

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    55 result(s) found for: Tar. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2017-002223-25 Sponsor Protocol Number: NL60891.091.17 Start Date*: 2018-05-25
    Sponsor Name:Radboud University Medical Center
    Full Title: Pilot study on the effect of prophylactic versus therapeutic treatment with coal tar and vaseline lanette ointment on the skin barrier repair mechanisms in absence of a chronic inflammatory compone...
    Medical condition: Atopic dermatits
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10003639 Atopic dermatitis LLT
    20.0 100000004858 10003640 Atopic dermatitis and related conditions LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-010863-18 Sponsor Protocol Number: NL26548.101.09 Start Date*: 2010-06-25
    Sponsor Name:Amphia ziekenhuis
    Full Title: The additive effect of short contact tar-derivates to UVB therapy in “en plaque” psoriasis: a prospective single blind unicenter randomized clinical trial
    Medical condition: Psoriasis patient getting UVB lighttherapy in a dermatological daycare center
    Disease: Version SOC Term Classification Code Term Level
    9.1 10015581 Exacerbation of psoriasis LLT
    9.1 10037153 Psoriasis LLT
    9.1 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-004542-28 Sponsor Protocol Number: NL59862.091.16 Start Date*: 2017-09-14
    Sponsor Name:Radboud University Medical Center
    Full Title: A randomized controlled pilot study comparing the efficacy of topical coal tar to topical corticosteroids in children aged 1 to < 16 years with moderate-severe atopic dermatitis.
    Medical condition: Atopic dermatitis
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-004687-19 Sponsor Protocol Number: NL59928.091.16 Start Date*: 2018-04-23
    Sponsor Name:Radboud University Medical Center
    Full Title: A randomized controlled trial evaluating the additional effect of topical coal tar to a topical corticosteroid regimen in patients aged >16 years of age with moderate-severe atopic dermatitis.
    Medical condition: Atopic Dermatitis (AD)
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-006127-34 Sponsor Protocol Number: 1.3 Start Date*: 2021-09-17
    Sponsor Name:Verein zur Förderung der Wissenschaft und Forschung an der 1.Med. Abteilung der Krankenanstalt Rudolfstiftung
    Full Title: Empagliflozin as potential treatment option for postprandial hyperinsulinemic hypoglycaemia after bariatric surgery – a pilot study
    Medical condition: Postprandial hyperinsulinemic hypoglycaemia (PHH) typically occurs years after bariatric surgery and one to three hours after a carbohydrate-rich meal. It is caused by rapid gastric emptying of und...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-000151-10 Sponsor Protocol Number: TAR-PRO Start Date*: 2017-08-02
    Sponsor Name:Fundación para la Investigación Biomédica del Hospital Universitario La Paz
    Full Title: Antiretroviral therapy proviral genotype-guided: pilot-proof of concept clinical trial.
    Medical condition: Human Immunodeficiency Virus
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-000444-58 Sponsor Protocol Number: CT041-ADO09 Start Date*: 2021-02-12
    Sponsor Name:Adocia
    Full Title: A Phase 2 Trial to Assess the Efficacy and Safety of M1 Pram P037 prandial insulin in T1DM subjects
    Medical condition: Type 1 diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    21.1 10027433 - Metabolism and nutrition disorders 10067584 Type 1 diabetes mellitus PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-002882-20 Sponsor Protocol Number: Start Date*: 2019-04-17
    Sponsor Name:Imperial College London
    Full Title: A multicentre randomised controlled trial to assess the safety and efficacy of adding rituximab to standard of care in treating acute antibody-mediated rejection in kidney transplantation (Transpla...
    Medical condition: Renal Transplant antibody-mediated rejection
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10023439 Kidney transplant rejection PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2007-006302-13 Sponsor Protocol Number: CT-BI Vacc-4x 2007/1 Start Date*: 2008-06-04
    Sponsor Name:Bionor Immuno AS
    Full Title: A Phase II, Randomized, Double-Blind, Multicenter, Immunogenicity Study of Vacc-4x Versus Placebo in Patients Infected with HIV-1 Who Have Maintained an Adequate Response to ART
    Medical condition: HIV positive subjects who have been clinically stable on antiretroviral therapy for the last six months with a viral load less than 50 copies/mL for the last six months and a CD4 cell count => 400 ...
    Disease: Version SOC Term Classification Code Term Level
    12.0 10020161 HIV infection LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) ES (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-004506-64 Sponsor Protocol Number: 17000139BLC3002 Start Date*: 2023-01-09
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 3, Open-Label, Multi-Center, Randomized Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG...
    Medical condition: BCG-naïve High-Risk Non-Muscle Invasive Bladder Cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10046714 Urothelial carcinoma bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned) PT (Trial now transitioned) BE (Trial now transitioned) FR (Trial now transitioned) NL (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-021356-26 Sponsor Protocol Number: 111679 Start Date*: 2011-01-03
    Sponsor Name:GlaxoSmithKline Biologicals
    Full Title: A Phase IIb, randomized, observer-blind, placebo controlled, multicenter primary/booster therapeutic vaccination study to determine efficacy and safety of F4co/ AS01B vaccine, administered intramus...
    Medical condition: ART-naïve HIV-infected adults (ART: anti-retroviral therapy)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10020161 HIV infection PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2005-005950-33 Sponsor Protocol Number: DOMPCCHSSWE1 Start Date*: 2006-06-07
    Sponsor Name:Karolinska Universitetssjukhuset
    Full Title: Studie av Domperidon och barn med kongenitalt centralt hypoventilationssyndrom.
    Medical condition: Congenital central hypoventilation syndrome, CCHS or Ondine's curse.
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2005-000707-34 Sponsor Protocol Number: 2316 Start Date*: 2011-11-08
    Sponsor Name:The Newcastle upon Tyne Hospitals NHS Trust
    Full Title: The induction of apoptosis by anti-psoriatic treatments
    Medical condition: Psoriasis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-000950-30 Sponsor Protocol Number: HPH116-104-PoC-2007 Start Date*: 2007-09-05
    Sponsor Name:H-PHAR,sa
    Full Title: Estudio piloto, doble ciego, aleatorizado, controlado con placebo, de dosis repetida, para la evaluación de la seguridad y la eficacia antiviral de HPH116 en pacientes infectados por VIH-1 que no h...
    Medical condition: Enfermedad medica investigada = SIDA (pacientes infectados con VIH-1) Pacientes infectados por VIH-1 que no hayan recibido tratamiento previo recibirán 600 mg ó 1200 mg de HPH116 dos veces al día f...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020180 HIV positive LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-006227-31 Sponsor Protocol Number: 0881X1-4503 Start Date*: 2009-01-09
    Sponsor Name:Medical Faculty, Otto-von-Guericke-University Magdeburg
    Full Title: Inflammatory Topoproteome of Psoriasis under Etanercept Treatment
    Medical condition: Patients with a severe psoriasis will be treated with Enbrel (Etanercept) 2 x 50 mg s.c. per week over 12 weeks (n = 6 patients). The treatment follows rigorously the approved label of the drug. Th...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-024527-25 Sponsor Protocol Number: CRAD001H2307 Start Date*: 2013-07-23
    Sponsor Name:Novartis Farma SpA
    Full Title: A 24 month, randomized, controlled, study to evaluate the efficacy and safety of concentration-controlled everolimus plus reduced tacrolimus compared to standard tacrolimus in recipients of living ...
    Medical condition: Adults with end stage liver disease patients requiring a liver transplant.
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004865 10024716 Liver transplantation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-000322-66 Sponsor Protocol Number: CRAD001A2433 Start Date*: 2013-11-07
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 24 month, multicenter, randomized, open-label safety and efficacy study of concentration-controlled everolimus with reduced calcineurin inhibitor vs mycophenolate with standard calcineurin inhibi...
    Medical condition: Adult kidney transplant recipients.
    Disease: Version SOC Term Classification Code Term Level
    19.0 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed) SK (Completed) ES (Completed) PT (Completed) AT (Completed) NL (Completed) BE (Completed) GR (Completed) CZ (Completed) SI (Completed) BG (Completed) PL (Completed) HR (Completed) NO (Completed) SE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2010-018279-99 Sponsor Protocol Number: HUM07-066 Start Date*: 2010-05-05
    Sponsor Name:Faculty of Medicine, Otto-von-Guericke-University Magdeburg
    Full Title: Skin Topoproteome under Adalimumab (Humira®) Treatment in Patients with Moderate to Severe Psoriasis
    Medical condition: Disease under investigation: Adult patients of both genders with moderate to severe chronic plaque psoriasis who failed to respond to or who have a contraindication to, or are intolerant to other s...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-001774-88 Sponsor Protocol Number: TAR-ORI-SD001 Start Date*: 2007-11-15
    Sponsor Name:Targanta Therapeutics Corporation
    Full Title: Nuvocid™ (oritavancin) at Single or Infrequent Doses for the Treatment of Complicated Skin and Skin Structure Infections (SIMPLIFI)
    Medical condition: Complicated skin and skin structure infections (cSSSI).
    Disease: Version SOC Term Classification Code Term Level
    9.1 10040872 Skin infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-001697-26 Sponsor Protocol Number: 055-006 Start Date*: 2011-12-12
    Sponsor Name:Professor Reich
    Full Title: Optimising outpatient care in mild to moderate psoriasis by a newly developed ‘Topical Treatment Optimising Programme’ - an international study using Daivobet®/Dovobet® Gel (‘PSO-TOP’)
    Medical condition: Mild to moderate active plaque psoriasis despite topical psoriasis treatment
    Disease: Version SOC Term Classification Code Term Level
    14.1 10040785 - Skin and subcutaneous tissue disorders 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DK (Completed) IT (Completed) DE (Completed) GB (Completed) NL (Completed) ES (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 22:59:34 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA